Catalyst Event

Pfizer Inc (PFE) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

3/24/2026, 12:00:00 AM

OtherSentiment: Positive

Pfizer and partner Valneva announced on March 24, 2026, their intention to seek regulatory approval for their Lyme disease vaccine candidate (VLA15/PF-07307405) following positive Phase 3 trial results showing over 70% efficacy. This is estimated to have a medium impact as it addresses a significant unmet medical need.

Korean Translation

화이자와 파트너사 발네바는 2026년 3월 24일, 3상 임상시험에서 70% 이상의 효능을 보인 라임병 백신 후보물질(VLA15/PF-07307405)에 대한 규제 승인을 추진할 것이라고 발표함. 미충족 의료 수요가 높은 분야로 상당한 시장 영향이 예상됨.

Related Recent Events

View Full Timeline